Still SF [Two-Stage / GS Designs]

posted by ElMaestro  – Belgium?, 2016-10-06 22:13  – Posting: # 16702
Views: 10,383

Hello VStus,

» But back to reality: isn't it more practical in case of HVD to perform pilot on development with let's say 50% power (wondering: replicated pilot to keep reasonable small population?), better understand in-vitro in-vivo relationship, optimize formulation and than run replicate scaled trial? In 2-stage we also need to wait for results from the 1st stage...

Yes
Nitpicking: you perform a 2-stage trial or a pilot trial because you do not know the variability, right? Which means the "let's say 50% power" in actuality means guessworking. Optimizing the formulation on basis of a pilot trial with inherently low power (=high uncertainty on the PE) is in scientific terms as solid as tarot cards or crystal healing.
I read on LinkedIn the other day: "The flat earth society has members all over the globe" :-D:-D:-D

OK, surely I will get in trouble for this post.
:pirate:

I could be wrong, but...
Best regards,
ElMaestro

Complete thread:

Activity
 Admin contact
20,135 posts in 4,245 threads, 1,385 registered users;
online 28 (1 registered, 27 guests [including 9 identified bots]).
Forum time (Europe/Vienna): 10:38 CET

In the beginner’s mind there are many possibilities.
In the expert’s mind there are few.    Shunryu Suzuki

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5